CSI Market
Sign In | Register

Zentalis Pharmaceuticals Inc (ZNTL) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access ZNTL quarterly Cash Flow →
Observing cash flow movements over recent quarters helps explain how Zentalis Pharmaceuticals Inc adapts cash usage as operating conditions change.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-137.06
Depreciation & amortization0.74
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Other Asset Impairment Charges4.14
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment-0.66
Share-based Compensation20.72
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Recognized Tax Gain On Intangible Asset Impairment-
Deconsolidation Gain Loss Amount Net-
Operating Lease Impairment Loss-
License Revenue Noncash-
Equity Securities Fv Ni Realized Gain Loss-
Noncash To Acquire In Process Research And Development-
Equity Securities Fv Ni Gain Loss-
Increase Decrease In Operating Lease Right Of Use Assets And Liabilities Net-
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable5.00
Increase (Decrease) in Accounts Payable and Accrued Liabilities-17.32
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets2.99
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-3.80
Discontinued operations0.00
Net Cash flow from Operating Activities-125.25
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.70
Proceeds from Maturities, Prepayments and Calls of Available-for-sale Securities250.00
Payments to Acquire Available-for-sale Securities, Debt-139.49
Real Estate Investments0.00
Proceeds From Sale Of Equity Securities Fv Ni20.41
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Cash Divested from Deconsolidation0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities131.62
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock-4.28
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-36.53
Capital Expenditures Incurred But Not Yet Paid-
Right Of Use Asset Obtained In Exchange For Operating Lease Liability-
Stock Issuance Costs Incurred But Not Yet Paid-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents36.53
Share Based Payment Arrangement Net Settlement Of Restricted Stock Unit Vesting-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-4.28
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-124.55
Total Cash Flow2.09
4 historic quarters locked

Sign in to unlock the full Zentalis Pharmaceuticals Inc cash flow history.

Sign In Create Free Account

About Zentalis Pharmaceuticals Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001725160-26-000014

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License